tirzepatide chemical structure Development of and the corresponding Tirzepatide (LY3298176) sodium | GIP/GLP-1

Orforglipron has completed Phase 3 clinical trials showing weight loss in the range of 12 to 14 percent over 36 to 72 weeks

Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, et al

The platforms AI doctor provides personalized, modern medical advice by synthesizing the latest peer-reviewed research

Despite its celebrated performance for treatment and control of schistosomiasis and other platyhelminth infections, praziquantel has some shortcomings and the inability of this drug to counteract disease sequelae prompts the need for novel therapeutic strategies

animal studies show risks

Therefore, they do not come with the same assurances of testing, efficacy, and testing as approved pharmaceuticals